SeaSpine Holdings (SPNE) Commences Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls more than 3% on weaker global demand outlook and US crude buildup
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
SeaSpine Commences Public Offering of Common Stock
January 7, 2020 4:03 PM ESTCARLSBAD, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE) (SeaSpine or the Company), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by SeaSpine.
Piper Sandler & Co. and Canaccord Genuity LLC are acting as joint book-running managers, SunTrust Robinson Humphrey, Inc. is acting as lead manager and BTIG, LLC and Ladenburg Thalmann & Co. Inc. are acting as co-managers for the... More
SeaSpine Announces Preliminary Results for Fourth Quarter and Full-Year 2019; Reports Record Revenue, Driven by Greater Than 20% U.S. Spinal Implants Growth
January 7, 2020 4:00 PM ESTCARLSBAD, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today preliminary financial results for the fourth quarter and full-year 2019, with U.S Spinal Implants revenues expected to reflect growth within the 20% to 21% range.Â
We are pleased by our overall strong revenue performance in the fourth quarter and, in particular, the growth in excess of 20% in the U.S. Spinal Implants portfolio, said Keith Valentine, President and Chief Executive Officer. Based on the rapid... More
